Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Area of Science:

• Cardiovascular Research
• Pharmacology
• Clinical Trials

Background:

• Non-COX-1-dependent platelet function (NCDPF) exhibits variability during aspirin therapy.
• Standardized assays and established reproducibility for NCDPF are lacking.
• Understanding aspirin's temporal effects on platelet function is crucial.

Purpose of the Study:

• To develop an integrated metric, the platelet function score (PFS), for non-COX-1-dependent platelet function (NCDPF).
• To assess the temporal response of NCDPF to aspirin in healthy volunteers and diabetic patients.
• To evaluate the reproducibility and clinical utility of the developed NCDPF metric.

Main Methods:

• Administered 325 mg/day aspirin to healthy volunteers (HV1, HV2) and diabetics (DM).
• Measured NCDPF using aggregometry (epinephrine, collagen, ADP) and PFA100 (collagen/epi) at baseline, post-dose, and final time points.
• Assessed COX-1 activity via arachidonic acid aggregometry (AAA) and derived PFS using principal components analysis.

Main Results:

• The developed platelet function score (PFS) strongly correlated with individual NCDPF measures.
• Final PFS after several weeks of aspirin was higher and strongly correlated with post-dose PFS.
• Individual NCDPF changes during aspirin therapy were inversely proportional to initial post-dose levels, indicating dynamic responses.

Conclusions:

• The platelet function score (PFS) effectively summarizes multiple NCDPF measures.
• Despite COX-1 suppression, NCDPF demonstrates predictable dynamics during aspirin therapy.
• Individuals with high NCDPF show continued decline, while those with low NCDPF return to baseline levels over time.